Equity · Currency in GBp · Last updated Aug 1, 2026
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers InSight Denials to analyze, track, trend, and report on denial data; Trisus Healthcare Intelligence, a solution that provides insights into resource consumption on the patient level; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentrex 330; Referral Verification System; and Sentry Core, a solution that simplifies the complexities of pharmacy procurement, utilization, and compliances. Further, it offers appeal and professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
CRW.L's Sharpe Ratio of -0.98 indicates that for each unit of volatility, it generates -0.98 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Aug 1, 2026).
Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.
CRW.L Sharpe Ratio Rank
Concerning
CRW.L ranks above 4.9% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating weak returns relative to total risk taken. Securities are ranked from 0 (worst) to 100 (best).
What moves the rank
Strong returns with low total volatility → Higher rank
High volatility (both upside and downside) → Lower rank
Consistent returns → Higher rank than volatile returns of same magnitude
Sharp drawdowns increase volatility → Lower rank
What you can do with this information
Weak risk-adjusted returns relative to category peers
Evaluate whether this holding aligns with your risk-return objectives
Consider reducing exposure or re-evaluating position size
Review higher-ranked alternatives in the same category
CRW.L Sharpe Ratio Market Positioning
The chart shows CRW.L's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.
CRW.L: -0.98
S&P 500 Index: 1.29
Red zone (bottom 25%): -0.43 or lower
Yellow zone (middle 50%): -0.43 to 0.99
Green zone (top 25%): 0.99 or higher
Top 1%: 4.26+
Median: 0.14 — half of all investments score higher
How it compares to other similar stocks
The table compares Craneware plc's Sharpe Ratio with other stocks in the Health Information Services industry across multiple time periods, showing how CRW.L's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Aug 1, 2026.
How much price history to include in the calculation
1 year
Historical Sharpe Ratio
The chart shows CRW.L's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when CRW.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading charts...
Sharpe Ratio Calculator
How does CRW.L fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
